Drug Approval | June 27, 2023
USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
Effective disaster response and management is a collaborative work
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Subscribe To Our Newsletter & Stay Updated
